Xdemvy (Lotilaner) Patent Expiration, LOE Window & CMS Spending

Xdemvy (Lotilaner) by Tarsus: FDA Orange Book core substance LOE 2030-01-17 (last listed 2038-12-14), 0 AB generics, $123.4M 2024 CMS Part D & Medicaid spend, and $1,850 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTarsus
FDA Application & PathwayN217603 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2030-01-17
Last Listed Patent or Exclusivity Date2038-12-14
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$123.4M
2024 Medicare Part D Spend$114.3M
2024 Medicaid Spend$9.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,850 intro WAC)